CagriSema Reduces Blood Pressure in Adults With Overweight or Obesity: REDEFINE 1.

ABSTRACT:

Background

Fixed-dose combination of semaglutide/cagrilintide (CagriSema 2.4 mg/2.4 mg) has demonstrated significant and clinically relevant body weight reductions in adults with overweight or obesity compared with placebo.

Methods

The phase 3a, 68-week REDEFINE 1 trial randomized adults without diabetes with body mass index ≥30 kg/m², or ≥27 kg/m² with ≥1 obesity-related complication, to once-weekly CagriSema 2.4 mg/2.4 mg, semaglutide 2.4 mg, cagrilintide 2.4 mg, or placebo, plus lifestyle intervention. Secondary and post hoc analyses evaluated the antihypertensive effect from REDEFINE 1, focusing on CagriSema and placebo groups, by subgroup/category, including baseline body mass index, the presence of hypertension or resistant hypertension at baselin

SUBMITTER: Verma S 

PROVIDER: S-EPMC12822771 | biostudies-literature | 2026 Feb

REPOSITORIES: biostudies-literature